Marwood Group

We're proud be to sponsoring the 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐢𝐜𝐞 𝐑𝐞𝐢𝐦𝐛𝐮𝐫𝐬𝐞𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐜𝐜𝐞𝐬𝐬 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 next month! Connect with our team in Nashville to learn more about the evolving landscape of reimbursement strategy, payer engagement, and market access for innovative medical technologies. Save 20% on registration with code MARWOOD https://lnkd.in/etg-k9p5

Connect with us in Denver this month at the Healthcare Financial Management Association (HFMA) annual conference to learn how our Performance Improvement team can help your organization optimize revenue enhancement, cost reduction, and operational transformation https://lnkd.in/eDbAvHZb

𝐌𝐚𝐫𝐰𝐨𝐨𝐝 𝐆𝐫𝐨𝐮𝐩’𝐬 𝐏𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭 𝐏𝐫𝐚𝐜𝐭𝐢𝐜𝐞 𝐀𝐝𝐝𝐬 𝐎𝐬𝐢 𝐔𝐝𝐞𝐳𝐢 𝐚𝐬 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫 𝐨𝐟 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐂𝐲𝐜𝐥𝐞 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 Marwood Group announced today the appointment of Osi Udezi, MHA as Director of Revenue Cycle Transformation for the Performance Improvement Practice. This practice works with leading healthcare clients to optimize financial and operational performance. This includes working with corporate healthcare clients and PE-backed healthcare companies focused on revenue enhancement initiatives, cost reduction, and operational transformation activities. "𝘈𝘯 𝘪𝘯𝘤𝘳𝘦𝘢𝘴𝘪𝘯𝘨𝘭𝘺 𝘤𝘳𝘪𝘵𝘪𝘤𝘢𝘭 𝘢𝘳𝘦𝘢 𝘰𝘧 𝘧𝘰𝘤𝘶𝘴 𝘧𝘰𝘳 𝘰𝘶𝘳 𝘤𝘭𝘪𝘦𝘯𝘵 𝘳𝘦𝘮𝘢𝘪𝘯𝘴 𝘙𝘊𝘔 𝘱𝘳𝘰𝘤𝘦𝘴𝘴 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘢𝘵𝘪𝘰𝘯, 𝘮𝘢𝘳𝘨𝘪𝘯-𝘤𝘦𝘯𝘵𝘳𝘪𝘤 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘦𝘯𝘢𝘣𝘭𝘦𝘮𝘦𝘯𝘵, 𝘢𝘯𝘥 𝘤𝘰𝘴𝘵 𝘤𝘰𝘯𝘵𝘳𝘰𝘭. 𝘈𝘴 𝘸𝘦 𝘨𝘳𝘰𝘸 𝘰𝘶𝘳 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘥𝘦𝘭𝘪𝘷𝘦𝘳 𝘵𝘢𝘯𝘨𝘪𝘣𝘭𝘦 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 𝘧𝘰𝘳 𝘰𝘶𝘳 𝘤𝘭𝘪𝘦𝘯𝘵𝘴, 𝘸𝘦 𝘢𝘳𝘦 𝘦𝘹𝘤𝘪𝘵𝘦𝘥 𝘵𝘰 𝘣𝘳𝘪𝘯𝘨 𝘖𝘴𝘪 𝘰𝘯 𝘵𝘰 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘵𝘩𝘪𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘸𝘰𝘳𝘬, 𝘱𝘢𝘳𝘵𝘪𝘤𝘶𝘭𝘢𝘳𝘭𝘺 𝘩𝘦𝘭𝘱𝘪𝘯𝘨 𝘤𝘭𝘪𝘦𝘯𝘵𝘴 𝘮𝘢𝘹𝘪𝘮𝘪𝘻𝘦 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘱𝘦𝘳𝘧𝘰𝘳𝘮𝘢𝘯𝘤𝘦 𝘪𝘯 𝘢𝘯 𝘦𝘳𝘢 𝘰𝘧 𝘤𝘰𝘯𝘵𝘳𝘢𝘤𝘵𝘪𝘯𝘨 𝘳𝘦𝘪𝘮𝘣𝘶𝘳𝘴𝘦𝘮𝘦𝘯𝘵." said Marwood’s Senior Managing Director Lee Alvarez. Mr. Udezi serves as the Director of Revenue Cycle Transformation within the Performance Improvement practice, bringing over 15 years of experience in healthcare operations and revenue cycle/financial performance optimizations. Before joining Marwood, Mr. Udezi led multiple engagements across various healthcare organizations to impact net revenue improvement through process optimization, system conversions, and overall business process and organizational transformations. His background includes pre-transaction advisory and post-transaction synergy capture for PE-backed physician and outpatient practice management, including integrating medical back-office operations for improved efficiencies, implementing best practices for improved patient access and flow across hospital departments, and enhancing financial performance through cash acceleration, net-revenue growth and cost take-out. Mr. Udezi holds a master’s degree in healthcare administration from the University of Illinois in Chicago and is a member of the American College of Healthcare Executives (ACHE) and the National Association of Health Services Executives (NAHSE) Learn more about Marwood's Performance Improvement Practice here: https://lnkd.in/e6GjwS5P

𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝗧𝗿𝘂𝗺𝗽 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀? This is the 𝘤𝘳𝘪𝘵𝘪𝘤𝘢𝘭 question of the moment, and Marwood Group's 𝗣𝗼𝗹𝗶𝘁𝗶𝗰𝘀 𝗮𝗻𝗱 𝗣𝗼𝗹𝗶𝗰𝘆 session with Joe Grogan and Walt Breakell will address just this at the Investors in Healthcare 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟱 next week. 𝗙𝗜𝗡𝗗 𝗢𝗨𝗧 𝗠𝗢𝗥𝗘 on the conference website here 👉 https://lnkd.in/ewpGFjYy Joe Grogan worked in the 𝗚𝗲𝗼𝗿𝗴𝗲 𝗪. 𝗕𝘂𝘀𝗵 𝗔𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 as 𝘌𝘹𝘦𝘤𝘶𝘵𝘪𝘷𝘦 𝘋𝘪𝘳𝘦𝘤𝘵𝘰𝘳 of the 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁’𝘀 𝗔𝗱𝘃𝗶𝘀𝗼𝗿𝘆 𝗖𝗼𝘂𝗻𝗰𝗶𝗹 on HIV and AIDS. He later joined the Food and Drug Administration (FDA) as a 𝘚𝘦𝘯𝘪𝘰𝘳 𝘗𝘰𝘭𝘪𝘤𝘺 𝘈𝘥𝘷𝘪𝘴𝘰𝘳 from which he joined the first 𝗧𝗿𝘂𝗺𝗽 𝗔𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 as 𝘈𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘦 𝘋𝘪𝘳𝘦𝘤𝘵𝘰𝘳 for 𝘏𝘦𝘢𝘭𝘵𝘩 𝘗𝘳𝘰𝘨𝘳𝘢𝘮𝘴 at the 𝗢𝗳𝗳𝗶𝗰𝗲 𝗼𝗳 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗕𝘂𝗱𝗴𝗲𝘁, managing a $1.3 trillion healthcare budget and shaping every major regulation issued by the 𝗗𝗲𝗽𝗮𝗿𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝗛𝘂𝗺𝗮𝗻 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀. As 𝘈𝘴𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘵𝘰 𝘵𝘩𝘦 𝘗𝘳𝘦𝘴𝘪𝘥𝘦𝘯𝘵 𝘢𝘯𝘥 𝘋𝘪𝘳𝘦𝘤𝘵𝘰𝘳 of the Domestic Policy Council, he was a key figure on The White House COVID-19 Task Force. In the private sector, Joe has worked for Gilead Sciences, is the 𝘚𝘵𝘳𝘢𝘵𝘦𝘨𝘪𝘤 𝘈𝘥𝘷𝘪𝘴𝘰𝘳 to the EU-US Forum, 𝘊𝘩𝘢𝘪𝘳𝘮𝘢𝘯 𝘰𝘧 𝘵𝘩𝘦 𝘉𝘰𝘢𝘳𝘥 of Paragon Health, and a 𝘯𝘰𝘯𝘳𝘦𝘴𝘪𝘥𝘦𝘯𝘵 𝘴𝘦𝘯𝘪𝘰𝘳 𝘴𝘤𝘩𝘰𝘭𝘢𝘳 at the USC Schaeffer Institute. Walt Breakell is an 𝘌𝘹𝘦𝘤𝘶𝘵𝘪𝘷𝘦 𝘝𝘪𝘤𝘦 𝘗𝘳𝘦𝘴𝘪𝘥𝘦𝘯𝘵 of Marwood working with a client base of financial sponsors and healthcare corporations in analysing regulatory and legislative issues, performing market analysis, and developing corporate strategy. He was previously a 𝘚𝘦𝘯𝘪𝘰𝘳 𝘈𝘥𝘷𝘪𝘴𝘰𝘳 to Hon. George E. Pataki, Governor, State of New York. #healthcare #investing #pharmaceuticals Heather Pfeiffer Grace Mackintosh

Less than a month until EHIA's Investors in Healthcare conference! Review the full agenda here: mrwd.co/EHIA_2025 featuring our Head of Life Sciences & HealthTech Nayan Ghosh speaking on Pharma commercialization, plus a special Healthcare policy Q&A with our EVP Walt Breakell

Join Holland & Knight’s #LifeSciences Team and the Marwood Group on May 22nd for a timely webinar exploring the legal, regulatory and #market dynamics of branded and compounded GLP-1s. Hear from Partner Michael Werner and Associate Sara Klock as they discuss evolving trends and regulatory scrutiny in the #GLP1 space. Register here: https://bit.ly/3RZlIVi

Labour’s policy agenda is reshaping the UK’s SEND landscape, with major implications for independent special schools and their investors. Download our latest whitepaper to learn more about the sector’s shifting funding dynamics, cost pressures, and strategic opportunities amid calls for greater inclusion and oversight mrwd.co/UKLabourSEND

Once a standout in the PPM space, #Dermatology is once again drawing strong interest from Private Equity investors. In our latest whitepaper, Marwood explores why this well-established sector is regaining momentum in 2025 - driven by consolidation opportunities, resilient reimbursement, and sustained demand. Read more: mrwd.co/DermWhitepaper

Italy: Join EHIA Strategic Partner Marwood Group and Associate Member Portolano Cavallo for a live discussion on the 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗣𝗵𝗮𝗿𝗺𝗮 & 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗶𝗻 𝗜𝘁𝗮𝗹𝘆 – 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗠𝗮𝘆 𝟭𝟰, 𝟭𝟱:𝟬𝟬 𝗖𝗘𝗦𝗧 We invite you to join an engaging and insightful webinar focused on the evolving Pharmaceutical and Biotechnology landscape in Italy. 👉 Register now to secure your spot: https://lnkd.in/etA2zWnb As Italy continues to refine its healthcare policies and regulatory framework, understanding the implications for life sciences companies is more important than ever. This session will provide a dive into the 𝗹𝗮𝘁𝗲𝘀𝘁 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗹𝗲𝗴𝗶𝘀𝗹𝗮𝘁𝗶𝘃𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀. A panel of experts will also discuss the 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 for pharmaceutical, biotech, and medtech companies 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗶𝗻 𝗼𝗿 𝘀𝗲𝗲𝗸𝗶𝗻𝗴 𝘁𝗼 𝗲𝗻𝘁𝗲𝗿 𝘁𝗵𝗲 𝗜𝘁𝗮𝗹𝗶𝗮𝗻 𝗺𝗮𝗿𝗸𝗲𝘁. 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝘁𝗵𝗶𝘀 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗴𝗮𝗶𝗻 𝗲𝘅𝗽𝗲𝗿𝘁 𝗶𝗻𝘀𝗶𝗴𝗵𝘁 𝗮𝗻𝗱 𝗽𝗿𝗲𝗽𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝗼𝗿𝗴𝗮𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗶𝗻 𝗼𝗻𝗲 𝗼𝗳 𝗘𝘂𝗿𝗼𝗽𝗲’𝘀 𝗸𝗲𝘆 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗺𝗮𝗿𝗸𝗲𝘁𝘀. 👉 Register now to secure your spot: https://lnkd.in/etA2zWnb #lifesciences #pharma #biotech #legislation #regulatory #italy Heather Pfeiffer Grace Mackintosh Nayan Ghosh Walt Breakell David DeAndrea Francesco Portolano Luca Gambini Andrea Gritti Elisa Stefanini Gianpaolo Scandone Manuela Cavallo Alessandro Tanno

Compounded alternatives to branded GLP-1s like Zepbound and Ozempic dominated the obesity and wellness markets during the GLP-1 shortage, allowing these alternatives to market at significantly lower prices and more varied distribution channels relative to those of Eli Lilly and Novo Nordisk. However, the end of the GLP-1 shortage earlier this year has prompted questions surrounding potential scrutiny from regulators and how the GLP-1 market could be reshaped. Join our next webinar with Holland & Knight LLP on Thursday May 22 at 1:00pm ET as our teams explore the evolving policy and commercial landscape for #GLP1s https://lnkd.in/eWcEbz69